Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/13/2025

Therapeutic Drug Monitoring for Voriconazole Therapy

Introduction to Voriconazole Therapy

  • The Infectious Diseases Society of America strongly recommends therapeutic drug monitoring for voriconazole due to high interindividual variability in drug metabolism and plasma concentrations 1

Patient Factors Influencing Voriconazole Metabolism

  • Allele frequency distribution varies by ethnicity, with higher frequencies of poor metabolism phenotypes in Asian populations and higher frequencies of rapid metabolism in non-Asian populations 2
  • Pediatric patients require higher weight-based dosing due to accelerated metabolic clearance, with a recommended maintenance dose of 7 mg/kg twice daily 2

Monitoring and Dosage Recommendations

  • Monitoring should be performed after reaching steady state (approximately 5-7 days), when adding or removing interacting medications, when changing dosage forms, when clinical response is inadequate, and when toxicity is suspected 1, 2
  • Target trough concentrations should be >1-1.5 μg/mL for efficacy and <5-6 μg/mL to minimize toxicity, and monitoring is essential due to nonlinear pharmacokinetics, high interpatient variability, and numerous drug-drug interactions 3

Special Considerations

  • Voriconazole is contraindicated during pregnancy due to fetal abnormalities observed in animals 1
  • In patients with renal impairment, the IV formulation should be avoided if CrCl <50 mL/min due to accumulation of cyclodextrin vehicle, and the oral formulation should be used instead 2
  • Patients with creatinine clearance <50 mL/min should be considered for oral formulation, and patients should be advised to avoid direct sunlight and use sun protection to minimize photosensitivity reactions 3, 4

Side Effects and Toxicity

  • Visual disturbances occur in approximately 30% of patients, typically manifesting as photopsia, color vision changes, and photophobia, and are usually self-limited and reversible, not clearly associated with absolute drug levels 3
  • Mild hepatotoxicity is common and related to drug concentration, manifesting as elevated liver enzymes, alkaline phosphatase, and bilirubin, and severe hepatotoxicity is uncommon but requires careful monitoring 3
  • Photosensitivity reactions occur in approximately 20% of patients, manifesting as skin rash, erythroderma, and perioral excoriations, and long-term use is associated with increased risk of squamous cell carcinoma and melanoma, especially in fair-skinned persons and immunosuppressed patients 3
  • Reversible central and peripheral neurologic symptoms, including visual or auditory hallucinations, encephalopathy, and peripheral neuropathy, correlate with higher drug concentrations 3
  • QT interval prolongation on electrocardiography, tachyarrhythmias, and rare cases of ventricular arrhythmias, including torsade de pointes, bradycardia, cardiac arrest, and sudden death, are associated with voriconazole use, especially in patients with a history of cardiotoxic chemotherapy, cardiomyopathy, hypokalemia, or concomitant QT-prolonging medications 3, 4

Monitoring and Follow-up

  • Baseline and periodic liver function tests, regular skin examinations, ECG monitoring, and visual symptom assessment are recommended for patients on voriconazole therapy 3, 4
  • Therapeutic drug monitoring is recommended due to nonlinear pharmacokinetics and high interpatient variability, and higher doses may be required in certain populations due to accelerated metabolic clearance 4, 2

Drug Interactions and Contraindications

  • Voriconazole is both a substrate and inhibitor of CYP2C19, CYP2C9, and CYP3A4, which can lead to significant interactions with multiple medications 3
  • Genetic polymorphisms in CYP2C19, concomitant medications that interact with CYP2C19 and CYP3A4, pre-existing liver dysfunction, and higher voriconazole trough concentrations are factors that require consideration when using voriconazole 3, 4